Loss or alteration of p53 in cancer cells can modulate the recruitment and activation of immune cells in the tumor microenvironment and can impact cytokine secretion within the TME, resulting in the suppression or evasion of anti-tumor immune responses and the promotion of cancer progression. This evidence concerns the gene TP53 and neoplasm.